BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients

por Bouchalova, K, Cizkova, M, Trojanec, R, Koudelakova, V, Radova, L, Furstova, J, Melichar, B, Cwiertka, K, Kharaishvili, G, Kolar, Z, Hajduch, M
Publicado 2011